Cargando…

Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma

BACKGROUND: Osteosarcoma is one of the most prevalent bone malignancies with a poor prognosis. The N7-methylguanosine (m7G) modification facilitates the modification of RNA structure and function tightly associated with cancer. Nonetheless, there is a lack of joint exploration of the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiming, Gan, Wenyi, Ru, Nan, Xue, Zhaowen, Chen, Wenjie, Chen, Zihang, Wang, Huajun, Zheng, Xiaofei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149372/
https://www.ncbi.nlm.nih.gov/pubmed/37139222
http://dx.doi.org/10.1016/j.jbo.2023.100481
_version_ 1785035149465878528
author Zhang, Yiming
Gan, Wenyi
Ru, Nan
Xue, Zhaowen
Chen, Wenjie
Chen, Zihang
Wang, Huajun
Zheng, Xiaofei
author_facet Zhang, Yiming
Gan, Wenyi
Ru, Nan
Xue, Zhaowen
Chen, Wenjie
Chen, Zihang
Wang, Huajun
Zheng, Xiaofei
author_sort Zhang, Yiming
collection PubMed
description BACKGROUND: Osteosarcoma is one of the most prevalent bone malignancies with a poor prognosis. The N7-methylguanosine (m7G) modification facilitates the modification of RNA structure and function tightly associated with cancer. Nonetheless, there is a lack of joint exploration of the relationship between m7G methylation and immune status in osteosarcoma. METHODS: With the support of TARGET and GEO databases, we performed consensus clustering to characterize molecular subtypes based on m7G regulators in all osteosarcoma patients. The least absolute shrinkage and selection operator (LASSO) method, Cox regression, and receiver operating characteristic (ROC) curves were employed to construct and validate m7G-related prognostic features and derived risk scores. In addition, GSVA, ssGSEA, CIBERSORT, ESTIMATE, and gene set enrichment analysis were conducted to characterize biological pathways and immune landscapes. We explored the relationship between risk scores and drug sensitivity, immune checkpoints, and human leukocyte antigens by correlation analysis. Finally, the roles of EIF4E3 in cell function were verified through external experiments. RESULTS: Two molecular isoforms based on regulator genes were identified, which presented significant discrepancies in terms of survival and activated pathways. Moreover, the six m7G regulators most associated with prognosis in osteosarcoma patients were identified as independent predictors for the construction of prognostic signature. The model was well stabilized and outperformed traditional clinicopathological features to reliably predict 3-year (AUC = 0.787) and 5-year (AUC = 0.790) survival in osteosarcoma cohorts. Patients with increased risk scores had a poorer prognosis, higher tumor purity, lower checkpoint gene expression, and were in an immunosuppressive microenvironment. Furthermore, enhanced expression of EIF4E3 indicated a favorable prognosis and affected the biological behavior of osteosarcoma cells. CONCLUSIONS: We identified six prognostic relevant m7G modulators that may provide valuable indicators for the estimation of overall survival and the corresponding immune landscape in patients with osteosarcoma.
format Online
Article
Text
id pubmed-10149372
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101493722023-05-02 Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma Zhang, Yiming Gan, Wenyi Ru, Nan Xue, Zhaowen Chen, Wenjie Chen, Zihang Wang, Huajun Zheng, Xiaofei J Bone Oncol Research Paper BACKGROUND: Osteosarcoma is one of the most prevalent bone malignancies with a poor prognosis. The N7-methylguanosine (m7G) modification facilitates the modification of RNA structure and function tightly associated with cancer. Nonetheless, there is a lack of joint exploration of the relationship between m7G methylation and immune status in osteosarcoma. METHODS: With the support of TARGET and GEO databases, we performed consensus clustering to characterize molecular subtypes based on m7G regulators in all osteosarcoma patients. The least absolute shrinkage and selection operator (LASSO) method, Cox regression, and receiver operating characteristic (ROC) curves were employed to construct and validate m7G-related prognostic features and derived risk scores. In addition, GSVA, ssGSEA, CIBERSORT, ESTIMATE, and gene set enrichment analysis were conducted to characterize biological pathways and immune landscapes. We explored the relationship between risk scores and drug sensitivity, immune checkpoints, and human leukocyte antigens by correlation analysis. Finally, the roles of EIF4E3 in cell function were verified through external experiments. RESULTS: Two molecular isoforms based on regulator genes were identified, which presented significant discrepancies in terms of survival and activated pathways. Moreover, the six m7G regulators most associated with prognosis in osteosarcoma patients were identified as independent predictors for the construction of prognostic signature. The model was well stabilized and outperformed traditional clinicopathological features to reliably predict 3-year (AUC = 0.787) and 5-year (AUC = 0.790) survival in osteosarcoma cohorts. Patients with increased risk scores had a poorer prognosis, higher tumor purity, lower checkpoint gene expression, and were in an immunosuppressive microenvironment. Furthermore, enhanced expression of EIF4E3 indicated a favorable prognosis and affected the biological behavior of osteosarcoma cells. CONCLUSIONS: We identified six prognostic relevant m7G modulators that may provide valuable indicators for the estimation of overall survival and the corresponding immune landscape in patients with osteosarcoma. Elsevier 2023-04-18 /pmc/articles/PMC10149372/ /pubmed/37139222 http://dx.doi.org/10.1016/j.jbo.2023.100481 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Zhang, Yiming
Gan, Wenyi
Ru, Nan
Xue, Zhaowen
Chen, Wenjie
Chen, Zihang
Wang, Huajun
Zheng, Xiaofei
Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
title Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
title_full Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
title_fullStr Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
title_full_unstemmed Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
title_short Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
title_sort comprehensive multi-omics analysis reveals m7g-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149372/
https://www.ncbi.nlm.nih.gov/pubmed/37139222
http://dx.doi.org/10.1016/j.jbo.2023.100481
work_keys_str_mv AT zhangyiming comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT ganwenyi comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT runan comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT xuezhaowen comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT chenwenjie comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT chenzihang comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT wanghuajun comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma
AT zhengxiaofei comprehensivemultiomicsanalysisrevealsm7grelatedsignatureforevaluatingprognosisandimmunotherapyefficacyinosteosarcoma